SCHEMBL50923

SCHEMBL50923

CN1CC=C(c2ccccc2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
QDPR P09417 2/20 0.67
KDM4E B2RXH2 1/20 0.53
LMNA P02545 1/20 0.53
POLB P06746 1/20 0.53
HTR1A P08908 1/20 0.53
ALOX15 P16050 1/20 0.53
SLC6A4 P31645 1/20 0.53
HTR6 P50406 1/20 0.53
HSD17B10 Q99714 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
KMT2A Q03164 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16862164 1.00 QDPR (0.67) QDPRKDM4ELMNAPOLBHTR1A
Hydrochloric Acid SCHEMBL1148906 0.98 QDPR (0.65) QDPRKDM4ELMNAPOLBHTR1A
Bromide SCHEMBL11557389 0.98 QDPR (0.65) QDPRKDM4ELMNAPOLBHTR1A
Ammonia Solution, Strong SCHEMBL15875021 0.98 QDPR (0.65) QDPRKDM4ELMNAPOLBHTR1A
SCHEMBL13898494 0.96 QDPR (0.68) QDPRKDM4ELMNAPOLBHTR1A
Hydrochloric Acid SCHEMBL19717522 0.96 QDPR (0.62) QDPRKDM4ELMNAPOLBHTR1A
SCHEMBL16565762 0.88 QDPR (0.53) QDPRNPC1RAB9AKMT2A
Hydrochloric Acid SCHEMBL6517404 0.84 QDPR (0.50) QDPRKDM4ELMNAPOLBHTR1A
SCHEMBL8264178 0.83 QDPR (0.59) QDPRSLC6A4
SCHEMBL7369176 0.83 QDPR (0.72) QDPRSLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 9108 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-121610414-B Saliva combined lactobacillus and application thereof in preparation of medicines for relieving parkinsonism 南昌大学 2026-05-12 CN claimed
EP-4713433-A2 LIVER ORGANOIDS WITH INTRAHEPATIC SYMPATHETIC NERVES, AND METHODS OF USE THEREOF Children's Hospital Medical Center (US) 2026-03-25 EP claimed
US-20260076969-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2026-03-19 US claimed
CN-121574923-A Construction method of parkinsonism-brain organoids and application of parkinsonism-brain organoids in screening parkinsonism treatment medicines 黑龙江中医药大学 2026-02-27 CN claimed
EP-4658795-A1 GENE THERAPY VECTORS FOR USE IN PARKINSON'S DISEASE Janssen Pharmaceutica NV (BE) 2025-12-10 EP claimed
EP-4652162-A1 INHIBITORS OF MPTP NRG Therapeutics LTD (GB) 2025-11-26 EP claimed
EP-4651954-A1 INHIBITORS OF MPTP NRG Therapeutics LTD (GB) 2025-11-26 EP claimed
US-20250228771-A1 ALKALINE INTRAORAL PRODUCTS EMPLICURE AB (publ) (SE) 2025-07-17 US claimed
CN-120157660-A Icaritin derivative and application thereof 青岛大学 2025-06-17 CN claimed
CN-120145652-A Welding beam engineering reliability design optimization method based on Kriging and sparrow search 电子科技大学 2025-06-13 CN claimed
EP-1212353-A4 SMALL CYCLIC MIMICS OF BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) UNIV MELBOURNE (AU) 2004-10-20 EP claimed
US-20030143208-A1 Oxidative stress-resistant cell lines and methods of use thereof CHILDREN'S HOSPITAL OF PHILADELPHIA, THE 2003-07-31 US claimed
US-20030108893-A1 Method for establishing neurogically relevant properties of a material SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2003-06-12 US claimed
US-20030023994-A1 Assay for toxin induced neuronal degeneration and viability in C. elegans NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-01-30 US claimed
WO-2003001197-A1 ASSAY FOR TOXIN INDUCED NEURONAL DEGENERATION AND VIABILITY IN C. ELEGANS VANDERBILT UNIVERSITY (US) 2003-01-03 WO claimed
EP-1212353-A1 SMALL CYCLIC MIMICS OF BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) THE UNIVERSITY OF MELBOURNE (AU) 2002-06-12 EP claimed
EP-0656791-B1 THERAPEUTIC COMPOSITIONS COMPRISING PQQ AND A REDUCING AGENT CHILDRENS MEDICAL CENTER (US) 2002-06-05 EP claimed
US-6232326-B1 SUFFICIENT TO REDUCE DOPAMINE LEVELS IN SUBCORTICAL AREAS OF THE BRAIN WITHOUT CAUSING SYMPTOMS OF PARKINSON'S DISEASE; PERMANENT OR LONG-TERM AMELIORATION OF SYMPTOMS ALPHA RESEARCH GROUP, LLC 2001-05-15 US claimed
WO-2000075176-A1 SMALL CYCLIC MIMICS OF BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) THE UNIVERSITY OF MELBOURNE (AU) 2000-12-14 WO claimed
WO-2000003713-A1 TREATMENT FOR SCHIZOPHRENIA AND OTHER DOPAMINE SYSTEM DYSFUNCTIONS NELSON JODI A (US) 2000-01-27 WO claimed